Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
178.11
-0.79 (-0.44%)
Apr 10, 2026, 4:00 PM EDT - Market closed
Axsome Therapeutics Employees
Axsome Therapeutics had 925 employees as of December 31, 2025. The number of employees increased by 242 or 35.43% compared to the previous year.
Employees
925
Change
242
Growth
35.43%
Revenue / Employee
$690,266
Profits / Employee
-$198,026
Market Cap
9.11B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 925 | 242 | 35.43% |
| Sep 30, 2025 | 816 | 209 | 34.43% |
| Jun 30, 2025 | 846 | 257 | 43.63% |
| Mar 31, 2025 | 712 | 143 | 25.13% |
| Dec 31, 2024 | 683 | 138 | 25.32% |
| Sep 30, 2024 | 607 | 105 | 20.92% |
| Jun 30, 2024 | 589 | 167 | 39.57% |
| Mar 31, 2024 | 569 | 176 | 44.78% |
| Dec 31, 2023 | 545 | 162 | 42.30% |
| Sep 30, 2023 | 502 | 150 | 42.61% |
| Jun 30, 2023 | 422 | 224 | 113.13% |
| Mar 31, 2023 | 393 | 277 | 238.79% |
| Dec 31, 2022 | 383 | 275 | 254.63% |
| Sep 30, 2022 | 352 | 246 | 232.08% |
| Jun 30, 2022 | 198 | 105 | 112.90% |
| Mar 31, 2022 | 116 | 46 | 65.71% |
| Dec 31, 2021 | 108 | 48 | 80.00% |
| Sep 30, 2021 | 106 | 53 | 100.00% |
| Jun 30, 2021 | 93 | 50 | 116.28% |
| Mar 31, 2021 | 70 | 25 | 55.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
AXSM News
- 5 days ago - Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 - GlobeNewsWire
- 6 weeks ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd. - GlobeNewsWire
- 2 months ago - Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 - GlobeNewsWire
- 3 months ago - Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue - GlobeNewsWire
- 3 months ago - FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars - Benzinga
- 3 months ago - Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission - GlobeNewsWire